(UroToday.com) Patients with microscopic hematuria can be of concern for bladder cancer; as a result, they should undergo extensive evaluation to rule out other possible causes. As such, the process of evaluation can mount up and be costly from all the diagnostic procedures and tests that are performed. To improve the cost-effectiveness of diagnosing bladder cancer in patients with microscopic hematuria, Dr. Greg Gin presented a podium presentation in which he introduced the use of a 10-plex immunoassay, Oncuria-Detect, to detect bladder cancer from collected voided urine in a comparison with the FDA-approved single-analyte BladderChekTM urine assay.
In this prospective multicenter study, Dr. Gin and his colleagues enrolled 292 patients with microscopic hematuria. A voided urine sample was collected from each patient for analysis by Oncuria-Detect, BladderChekTM, and urine cytology before cystoscopy with biopsy.
They found that of the 292 patients enrolled, 22 patients had bladder cancer. Oncuria-Detect was found to have the following detection performance: 82.0% sensitivity, 37.8% specificity, and a 97.5% adjusted negative predictive value (NPV). BladderChekTM was found to have the following detection performance: 9.3% sensitivity, 99.6% specificity, and 95.4% adjusted NPV. Urine cytology was found to have the following detection performance: 44.8% sensitivity, 99.3% specificity, and 97.2% adjusted NPV.
Dr. Gin concluded that Oncuria-Detect showed potential in this ongoing trial as a diagnostic tool to detect bladder cancer in patients with microscopic hematuria, performing well with a higher sensitivity than the FDA-approved BladderChekTM test as well as urine cytology.
Before the presentation conclusion, Dr. Gin was asked by the session moderator, Dr. Trushar Patel, if all the patients would undergo cystoscopy just for microscopic hematuria to which Dr. Gin responded that moderate to high risk patients with microscopic hematuria would undergo cystoscopy with the Oncuria-Detect assay being used to rule out patients to not undergo cystoscopy. The session ended with a final question by an audience member asking Dr. Gin if he had any experience with predicting response to therapy with this test to which Dr. Gin replied that he believes there is an ongoing trial with Oncuria-Detect for surveillance cystoscopy.
Presented by: Greg Gin, M.D., University of California, Irvine, USA during the 2026 American Urological Association (AUA) Annual Meeting, May 15 – May 18, 2026, Washington, D.C.
Written by: Victor Pham, B.S., University of California Irvine, @victorpham01 on X during the American Urological Association (AUA) 2026 Annual Meeting, Washington, DC, Fri, May 15 – Mon, May 18, 2026.
Related Content:
Detection of Bladder Cancer in Patients with Microscopic Hematuria Using Oncuria-Detect: Results of a Prospective, Multicenter International Study - Beyond the Abstract